Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Oct 5;73(7):1292-1295.
doi: 10.1093/cid/ciab485.

Gut Resistome of Preschool Children After Prolonged Mass Azithromycin Distribution: A Cluster-randomized Trial

Ahmed M Arzika  1 , Ramatou Maliki  1 , Amza Abdou  2   3 , Alio K Mankara  1 , Abdoul N Harouna  1 , Catherine Cook  4 , Armin Hinterwirth  4 , Lee Worden  4 , Lina Zhong  4 , Cindi Chen  4 , Kevin Ruder  4 , Zhaoxia Zhou  4 , Elodie Lebas  4 , Kieran S O'Brien  4 , Catherine E Oldenburg  4   5   6 , Victoria Le  4 , Benjamin F Arnold  4 , Travis C Porco  4   5   6 , Jeremy D Keenan  4   5   6 , Thomas M Lietman  4   5   6   7 , Thuy Doan  4   5
Affiliations
Randomized Controlled Trial

Gut Resistome of Preschool Children After Prolonged Mass Azithromycin Distribution: A Cluster-randomized Trial

Ahmed M Arzika et al. Clin Infect Dis. .

Abstract

We evaluated the gut resistome of children from communities treated with 10 twice-yearly azithromycin distributions. Although the macrolide resistance remained higher in the azithromycin arm, the selection of non-macrolide resistance observed at earlier time points did not persist. Longitudinal resistance monitoring should be a critical component of mass distribution programs.

Clinical trials registration: NCT02047981.

Keywords: Niger; antibiotic resistance; azithromycin; gut resistome; mass drug distribution; preschool children.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Gut antimicrobial resistance determinants of children 6 months after the 10th twice-yearly oral azithromycin distribution. Factor difference of antibiotic resistance determinants in the azithromycin treated group compared to the placebo treated group with associated 95% confidence interval (95% CI).
See this image and copyright information in PMC

References

    1. Doan T, Worden L, Hinterwirth A, et al. . Macrolide and nonmacrolide resistance with mass azithromycin distribution. N Engl J Med 2020; 383:1941–50. - PMC - PubMed
    1. Susuman AS, Chialepeh WN, Bado A, Lailulo Y. High infant mortality rate, high total fertility rate and very low female literacy in selected African countries. Scand J Public Health 2016; 44:2–5. - PubMed
    1. Doan T, Hinterwirth A, Worden L, et al. . Gut microbiome alteration in MORDOR I: a community-randomized trial of mass azithromycin distribution. Nat Med 2019; 25:1370–6. - PubMed
    1. Doan T, Arzika AM, Hinterwirth A, et al. ; MORDOR Study Group . Macrolide resistance in MORDOR I: a cluster-randomized trial in Niger. N Engl J Med 2019; 380:2271–3. - PMC - PubMed
    1. Lakin SM, Dean C, Noyes NR, et al. . MEGARes: an antimicrobial resistance database for high throughput sequencing. Nucleic Acids Res 2017; 45:D574–80. - PMC - PubMed

Publication types

MeSH terms

Associated data